Company Overview
| Stock Name | Bioheart-B |
|---|---|
| Stock Code | 02185 |
| Company Full Name | To be extracted |
| Industry | Healthcare |
| Principal Activities | 中國領先的創新介入式心血管裝置公司,專注於全降解支架(BRS)及腎神經阻斷(RDN)兩種療法,以解決冠狀或外周動脈疾病及未控高血壓、頑固性高血壓的未滿足醫療需求。 |
| Listing Date | 2021-12-23 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國上海市浦東新區張江高科技產業東區瑞慶路590號4幢3層302室 |
| Business Address (Hong Kong) | 香港銅鑼灣希慎道33號利園一期19樓1901室 |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | bio-heart.com |
| Share Registrar | 香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | Mechanism A |
|---|---|
| Offer Price | HK$ 21.25 / shares |
| Offer Price Range | Final offer price only, no range |
| Lot Size | 500 shares |
| Entry Threshold | HK$ 10,625 |
| Par Value | RMB 1.0 / shares |
| Offer Period | 2021-12-13 to 2021-12-16 |
| Global Offering Shares | 23,937,000 shares |
| HK Public Offer Shares (Initial) | 2,394,000 shares (10.0%) |
| Public Offer Lots (Initial) | 4,788lots (Pool A2,394lots,Pool B2,394lots) |
| International Placing Shares (Initial) | 21,543,000 shares (90.0%) |
| Offer Ratio | ~10.0% |
| Total Shares Post-IPO | 243,937,000 shares |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | To be extracted |
| Cornerstone Share | No cornerstone investors |
| Clawback Tiers | To be extracted |
| Reallocation Option | Yes |
| Total Global Offering Size | HK$ 508,661,250 |
Subscription Tiers
Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.
Pool A
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1 lots | 500 | HK$ 10,625 |
| 2 lots | 1,000 | HK$ 21,250 |
| 3 lots | 1,500 | HK$ 31,875 |
| 4 lots | 2,000 | HK$ 42,500 |
| 5 lots | 2,500 | HK$ 53,125 |
| 6 lots | 3,000 | HK$ 63,750 |
| 7 lots | 3,500 | HK$ 74,375 |
| 8 lots | 4,000 | HK$ 85,000 |
| 9 lots | 4,500 | HK$ 95,625 |
| 10 lots | 5,000 | HK$ 106,250 |
| 12 lots | 6,000 | HK$ 127,500 |
| 14 lots | 7,000 | HK$ 148,750 |
| 16 lots | 8,000 | HK$ 170,000 |
| 18 lots | 9,000 | HK$ 191,250 |
| 20 lots | 10,000 | HK$ 212,500 |
| 24 lots | 12,000 | HK$ 255,000 |
| 28 lots | 14,000 | HK$ 297,500 |
| 32 lots | 16,000 | HK$ 340,000 |
| 40 lots | 20,000 | HK$ 425,000 |
| 50 lots | 25,000 | HK$ 531,250 |
| 60 lots | 30,000 | HK$ 637,500 |
| 100 lots | 50,000 | HK$ 1,062,500 |
| 200 lots | 100,000 | HK$ 2,125,000 |
| 300 lots | 150,000 | HK$ 3,187,500 |
| 400 lots | 200,000 | HK$ 4,250,000 |
Pool B
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 700 lots | 350,000 | HK$ 7,437,500 |
Stock Connect Inclusion Analysis
| 26Q4 Regular Review | |
| Inclusion Pathway | Regular Path |
|---|---|
| Avg Daily HK Mkt Cap | HK$ 689.8M |
| Est. Threshold | HK$ 9.71B |
| Analysis Result | HK market cap below threshold, need +1308% |
Valuation & Financials
| Market Cap (at Offer Price) | HK$ 5,183,661,250 |
|---|---|
| H-Share Market Cap (at Offer Price) | HK$ 1,309,129,965 |
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | 不适用(公司处于亏损状态) |
| Profit/Loss Status | 亏损人民币340.3百万元 |
| Period-End Cash Balance | 人民币453.7百万元 |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
Financial Data
Unit:
'000
RMB
Income Statement
| Item | 2019 |
|---|---|
| Other income and gains, net | 1,855 |
| Administrative expenses | -3,230 |
| Operating profit | -586 |
| Net finance costs | -108 |
| Profit before tax | -10,694 |
| Income tax expense | 0 |
| Profit for the year | -10,694 |
| Profit attributable to owners | -10,694 |
Balance Sheet
| Item | 2019 |
|---|---|
| Cash and cash equivalents | 16,219 |
| Total current assets | 19,648 |
| Total assets | 27,606 |
| Total current liabilities | 5,545 |
| Total liabilities | 7,097 |
| Total equity | 20,509 |
| Equity attributable to owners | 20,509 |
Cash Flow Statement
| Item | 2019 | 2020 | 2021-06 |
|---|---|---|---|
| Net cash from operating activities | -860 | ||
| Net cash from investing activities | 217 | ||
| Net cash from financing activities | -1,046 | ||
| Net increase in cash | -949 | ||
| Depreciation of PP&E | 6,795 | 7,537 | 5,468 |
| Depreciation of right-of-use assets | 905 | 1,106 | 1,725 |
| Purchase of PP&E | -14,989 | -5,747 | -10,116 |
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
| First Day Close | HK$ 20.1 |
|---|---|
| First Day Open | HK$ 18.88 |
| First Day Change | -5.41% |
| First Day Volume | 3952000.0 |
| First Day Turnover | 77091800.0 |
| Use of Proceeds | 1、62.0%,或273.9百萬港元用于撥付正在進行的確認性臨床試驗、注冊備案的籌備事宜以及我們的核心產品Bioheart?的計劃中商業化上市;
2、21.3%,或94.1百萬港元用于撥付在中國正在進行的隨機對照臨床試驗以及我們的腎神經阻斷在研產品第二代Iberis?的持續開發;
3、6.7%,或29.6百萬港元用于撥付我們管線中其他在研產品的研發、進行中臨床前研究及已規劃的臨床試驗;
4、10.0%,或44.2百萬港元作一般企業及營運資金用途。 |
Underwriting Syndicate
Sole Sponsor (1)
HUATAI FINANCIAL HOLDINGS (HONG KONG) LIMITED CE AOK809
Overall Coordinators (1)
HUATAI FINANCIAL HOLDINGS (HONG KONG) LIMITED CE AOK809
Joint Bookrunners (1)
HUATAI FINANCIAL HOLDINGS (HONG KONG) LIMITED CE AOK809
Joint Lead Managers (1)
HUATAI FINANCIAL HOLDINGS (HONG KONG) LIMITED CE AOK809
Cornerstone Investors
This stock has no cornerstone investors.
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 汪立 | — |
| Company Secretary | 王雲磬、郭兆瑩 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 汪立透過Winning Powerful Limited、上海百哈特、上海百心安通等合共持有約43.75%股權 |
|---|




